Investor Alert: Pomerantz Law Firm Investigates Immix Biopharma for Potential Securities Fraud
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Immix Biopharma, Inc. (NASDAQ: IMMX) and its officers or directors on behalf of investors. The investigation follows the abrupt termination of Richard Graydon as Chief Medical Officer in July 2026 after his appointment just three months earlier. Media reports revealed that Graydon's real name is Ronald L. Fischer, a fugitive from justice who disappeared during a rape trial in 2005 and was arrested recently following an inter-state law enforcement operation. The revelation caused Immix’s stock price to drop by $1.45 per share (or 14.15%) on July 20, closing at $8.80. Pomerantz LLP is a well-known firm in corporate and securities litigation with a long history of pursuing class-action lawsuits against companies for misconduct. Investors are encouraged to contact the law firm regarding potential claims.
Tickers: $IMMX
Topics: executive misconduct legal action securities fraud stock price drop